Long-term Real-Life Outcomes of the Clareon® Hydrophobic Intraocular Lens: the Clarte Study in 191 Eyes

To describe and analyze the real-life refractive, functional and safety outcomes of the Clareon® intraocular lens (IOL) after 3 years. Data was collected retrospectively for observational purposes between July 2017 and December 2019 in the ophthalmology department of Desgenettes military hospital in Lyon, France. Eyes that underwent cataract surgery with Claeron® implantation were consecutively included. Patients with a systemic or ocular condition that could affect the visual outcome were excluded. Postoperative corrected (CDVA) and uncorrected (UDVA) distance visual acuities as well as capsule and IOL transparency were assessed at 1 month and 3 years. A total of 326 eyes were analyzed at one month and 191 eyes were reassessed at the 3-year follow-up visit. At 3 years, the mean CDVA was 0.003 LogMAR (95 The Clareon® is a recent hydrophobic intraocular lens (IOL) that has shown high-performance functional and safety outcomes in published studies after a 1-year follow-up. What is new These good functional and safety outcomes were maintained over a 3-year follow-up. A low rate of Nd:YAG treatment was reported (4.7